Corrigendum: BI 1015550 is a PDE4B inhibitor and a clinical drug candidate for the oral treatment of idiopathic pulmonary fibrosis

Frontiers in Pharmacology

Pharmacology

Franziska Elena Herrmann¹  Lutz Wollin¹  Christian Hesslinger¹  Peter Nickolaus² 

[1] Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach an der Riss, Germany;null;

关键词: PDE4B;    IPF;    lung fibrosis;    phosphodiesterase;    cAMP;    ILDs;   

DOI  :  10.3389/fphar.2023.1219760

 received in 2023-05-09, accepted in 2023-05-22,  发布年份 2023

来源: Frontiers

【 授权许可】

Unknown   
Copyright © 2023 Herrmann, Hesslinger, Wollin and Nickolaus.